AI Generated Image
FDA approves Moderna flu shot made with mRNA : NPR
NPR • • general
Key Points:
- The FDA has approved Moderna's mRNA-based flu vaccine, mFLUSIVA, for people aged 50 and older, marking the first flu vaccine using mRNA technology similar to COVID-19 shots.
- Moderna's research involving over 40,000 participants showed mFLUSIVA is safe and offers stronger protection than traditional flu vaccines, with availability expected in time for the 2026-2027 flu season.
- The FDA's approval follows initial resistance influenced by political backlash and misinformation surrounding mRNA vaccines, but was ultimately supported by unanimous recommendation from an independent advisory panel.
- Public health experts highlight the advantages of mRNA vaccines, including faster updates and production, which could improve responses to emerging flu strains and potential pandemics.
- Despite praise from many health officials, some critics remain disappointed with the FDA's decision to approve the new mRNA flu vaccine.
